{"id":"a9368e8d-2745-5836-93eb-23cf59dcf0a9","stable_key":"74ef5bba-ee14-531c-b1bf-d1f297c56bb6:fisetin-mouse-oral-exposure","predicate":"produces","statement":"Mouse absolute oral fisetin bioavailability was reported as 7.8% at 100 mg/kg and 31.7% at 200 mg/kg; circulating geraldol exceeded parent exposure.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"1cd6d20b-e16d-5a96-acf4-5f548aa56125","mechanism_event_label":"Exposure did not scale as a simple fixed fraction of dose.","subject":{"id":"dee05061-c3f3-5226-8054-dd58b76a585d","slug":"fisetin","display_name":"Fisetin","entity_type_key":"small_molecule"},"object":{"id":"a3b715d6-8cf9-5a5a-949a-dbd93af40aa3","slug":"mouse-fisetin-oral-bioavailability","display_name":"Mouse oral fisetin bioavailability","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1cd6d20b-e16d-5a96-acf4-5f548aa56125","stable_key":"74ef5bba-ee14-531c-b1bf-d1f297c56bb6:fisetin-mouse-oral-exposure-event","event_type":"observed_relationship","label":"Exposure did not scale as a simple fixed fraction of dose.","description":"Mouse absolute oral fisetin bioavailability was reported as 7.8% at 100 mg/kg and 31.7% at 200 mg/kg; circulating geraldol exceeded parent exposure.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"dee05061-c3f3-5226-8054-dd58b76a585d","slug":"fisetin","display_name":"Fisetin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a3b715d6-8cf9-5a5a-949a-dbd93af40aa3","slug":"mouse-fisetin-oral-bioavailability","display_name":"Mouse oral fisetin bioavailability","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"9fdb2610-ab87-5de2-9658-ed83bc42b3fc","slug":"geraldol","display_name":"Geraldol / 3-prime-O-methylfisetin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Mouse oral/intravenous LC-MS/MS pharmacokinetic study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"These are mouse regimen-specific estimates, not human absorption percentages.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Fisetin collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"fisetin","display_name":"Fisetin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Exposure did not scale as a simple fixed fraction of dose.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Identification of absolute conversion to geraldol from fisetin and pharmacokinetics in mouse. · 2016 · https://pubmed.ncbi.nlm.nih.gov/27810278/ · DOI 10.1016/j.jchromb.2016.10.034","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"f2388890-d824-5ef5-80c6-9dba4ad5affa","evidence_kind":"source_excerpt","locator":"Lines 48-54","start_line":48,"end_line":54,"excerpt":"## fisetin-mouse-oral-exposure\nExposure did not scale as a simple fixed fraction of dose.\nMouse absolute oral fisetin bioavailability was reported as 7.8% at 100 mg/kg and 31.7% at 200 mg/kg; circulating geraldol exceeded parent exposure.\nModel: Mouse oral/intravenous LC-MS/MS pharmacokinetic study.\nLimitations: These are mouse regimen-specific estimates, not human absorption percentages.\nEvidence access: Primary abstract\nIdentification of absolute conversion to geraldol from fisetin and pharmacokinetics in mouse. · 2016 · https://pubmed.ncbi.nlm.nih.gov/27810278/ · DOI 10.1016/j.jchromb.2016.10.034","model_system":"Mouse oral/intravenous LC-MS/MS pharmacokinetic study.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1108bfff-6504-5152-a51f-ff3d7c27c282","stable_key":"import-74ef5bba-ee14-531c-b1bf-d1f297c56bb6","title":"Fisetin: metabolism, cell-state responses and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"c30e0764cd34bd062cfcbfaf32357ef29dfda30e7d4153c545178140f5054e09","revision_id":"40ff52c0-f4b9-5820-8abb-ff002c6364a4","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}